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ABSTRACT 
Uncoating is a poorly understood yet required step of HIV-1 replication that is defined as the 
disassembly of the viral capsid structure. The goal of this project is to characterize uncoating in 
C20 microglial cells. These cells are a natural target of HIV-1 that are infected to establish latent 
viral reservoirs and HIV-associated neurological disorders. A stable C20 cell line that expresses 
TRIM-CypA was established to study the kinetics of uncoating with the CsA washout assay. The 
expression of TRIM-CypA was confirmed by western blot and the functionality of the protein 
was confirmed by a viral infectivity assay. Using this cell line, uncoating was found to have an 
average half-life of 63.3 min. Viral fusion assays determined the kinetics of viral fusion in C20 
cells compared to uncoating. The average half-life of viral fusion was found to be 40.9 min. To 
characterize the effect of CsA on HIV infectivity in C20 cells a viral infectivity assay was 
performed in the presence and absence of CsA. It was discovered that HIV infectivity was 
slightly lower in the presence of CsA. The study of uncoating kinetics in microglial cells will 
give more insight on how HIV establishes infection in brain cells which contributes to a larger 
goal of developing better therapies, a vaccine, and ultimately, a cure to HIV. 
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INTRODUCTION 
 
Disease Relevance 
Human Immunodeficiency Virus (HIV) is the virus that can progress to the deadly 
disease known as Acquired Immunodeficiency Syndrome (AIDS). This virus infects cells of the 
immune system that express a CD4 receptor (CD4+ cells) which are responsible for identifying 
and coordinating an immune response to invading pathogens. Cells that express a CD4 receptor 
include T helper cells, monocytes, macrophages, and dendritic cells. Chemokine co-receptors 
such as C-C motif chemokine receptor 5 (CCR5) or C-X-C motif chemokine receptor 4 
(CXCR4) are common secondary receptors that HIV utilizes for infection in addition to the 
primary CD4 receptor.  As HIV infection progresses, more immune cells are destroyed and the 
immune system is increasingly damaged, making the body more susceptible to common 
infections and cancer. The progression from HIV to AIDS takes 8 to 10 years and is marked by 
extremely low T cell counts and an immune system that is unable to respond to infections.    
The HIV/AIDS pandemic is a global health concern. HIV is the world’s leading 
infectious disease killer with approximately 36 million people currently living with HIV/AIDS, 
many of which are unaware they are infected (UNAIDS, 2018). Individuals unaware of their 
infection status unknowingly contribute to the spread of the virus. Transmission of HIV follows 
three major routes: unprotected sexual contact, exposure to contaminated blood or bodily fluids, 
and perinatal transmission. The virus cannot be transmitted by air or water, saliva, sweat or tears, 
pets or insects, or sharing toilets, food and drinks (Centers for Disease Control and Prevention 
[CDC], 2019a).  The virus does not survive on surfaces and cannot reproduce on its own. The 
primary methods of transmission of HIV in the United States is sexual contact and sharing 
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syringes (CDC, 2019a). Various methods of prevention exist to decrease transmission of the 
virus. 
Antiretroviral therapy (ART) is a combination of drugs used to treat individuals who 
have been infected with HIV. These drugs target steps of the viral replication cycle to destroy 
viral infection. The recommended initial regimen for a patient recently diagnosed with HIV-1 is 
1 integrase strand transfer inhibitor (INSTI) and 2 nucleoside reverse transcriptase inhibitors 
(NRTI; (National Institute of Health, 2019)). This combination targets integration and reverse 
transcription of the virus. Strict adherence to drug regimen is the only way for therapy to be 
effective. If even one dose is missed, the virus quickly replicates and exponentially increases 
viral load. ART offers a way to treat side effects of HIV and keep viral load low but cannot cure 
an infected individual.  
Biomedical approaches such as pre-exposure prophylaxis (PrEP) and post-exposure 
prophylaxis (PEP) have been designed to utilize ART to stop the spread of HIV. PrEP is a 
medicine taken daily that, when regimen is adhered to, reduces the risk of getting HIV from sex 
by more than 90% and reduces the risk of those who inject drugs of contracting the virus by 
more than 70% (CDC, 2019b). This drug therapy is recommended for those who have an HIV 
positive partner or inject drugs and share needles. PEP is a drug therapy used to treat individuals 
who have been potentially exposed to HIV to prevent exposure from becoming an infection. PEP 
medication must be taken once or twice daily for 28 days and must be started within 72 hours of 
exposure (CDC, 2019c). These medications aim to keep transmission of HIV to a minimum for a 
healthier society.  
No vaccine or cure for HIV/AIDS exists, underscoring the need for additional research of 
the virus. Current research of HIV replication is conducted in cell lines that HIV infects in vivo, 
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as well as does not infect in vivo. In the human body, microglial cells are infected by HIV and 
are involved in HIV-associated neurological disorders (HAND). Thus, microglial cells should be 
used in further studies researching HIV infection. Expansion of the current knowledge of HIV 
replication can lead to new drug targets, therapies, and a vaccine. 
 
HIV Replication Cycle 
Early replication. The HIV-1 replication cycle is a nine-step process that can be divided 
into two parts: early and late replication. The early steps of HIV-1 replication establish infection 
of the host cell. Binding of the viral envelope to specific receptors on the cell surface initiates 
infection. The viral envelope is made up of a two-part glycoprotein complex, with gp120 being 
the surface glycoprotein and gp41 being the transmembrane glycoprotein (Freed, 2001). Gp120 
first binds the CD4 receptor on a host cell through a high affinity interaction of the N-terminal 
extracellular domain of CD4 and a site located between the third and fourth conserved domain of 
gp120 (Freed, 2001). Once gp120 binds CD4, it undergoes a conformational change that 
increases the affinity for co-receptors CCR5 or CXCR4 and binds the co-receptor, creating a 
ternary complex between gp120, CD4, and a co-receptor (Freed, 2001). A conformational 
change occurs in gp41 that triggers the second step of HIV-1 replication known as membrane 
fusion. The ectodomain of gp41 is composed of a hydrophobic N-terminus called the fusion 
peptide, and 2 heptad repeat motifs called the N-helix and C-helix. When the ternary complex 
between gp120, CD4, and a co-receptor form, a rearrangement occurs in the N-helix and C-helix 
of gp41, resulting in fusion peptide insertion into the target membrane (Freed, 2001). In this step, 
gp41 acts to fuse the plasma membrane of the host cell and the lipid bilayer of the viral envelope, 
consequently releasing the viral capsid into the cytoplasm. The viral capsid is an outer protein 
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shell structure of the virus that surrounds viral RNA and viral proteins necessary for infection 
(Freed, 2001).  
Once in the cytoplasm, the capsid structure disassembles in a process called uncoating. 
At this step, the viral complex is called the reverse transcription complex (RTC) and includes 
several viral proteins such as matrix (MA), nucleocapsid (NC), reverse transcriptase (RT), 
integrase (IN), and viral protein R (Vpr). The viral RNA is reverse transcribed into double 
stranded DNA (dsDNA) while remaining associated with the RTC. Once reverse transcription is 
complete, the complex is referred to as the pre-integration complex (PIC). The PIC is trafficked 
to the nucleus with help from viral and cellular factors such as microtubules and motor proteins. 
At the nucleus, the complex containing the viral genome migrates through the nuclear pore 
complex. This is a capsid-dependent process called nuclear import, that is facilitated by host 
factors including cleavage and polyadenylation factor 6 (CPSF6), Transportin-3 (TNPO3), and 
NPC (Nuclear pore complex) proteins. Once inside the nucleus, integration occurs in which 
integrase inserts the viral dsDNA genome into the host cell chromosome.  Integration completes 
the early steps of HIV replication which are depicted in Figure 1.  At this stage, the viral DNA is 
called the provirus and acts a gene in the host cell (Freed, 2001).  
Late replication. The late steps of HIV-1 infection begin with transcription of the 
provirus to produce viral RNA molecules that are translated into functional proteins. The three 
polyproteins synthesized are Gag, Env, and Pol. Gag and Env polyproteins provide structure 
while Pol polypeptide provides enzymatic functions to the virus. Once the provirus is transcribed 
and translated, the newly produced viral proteins work together to form a virion.  
Following translation, the virus undergoes the steps of trafficking, assembly, budding, 
and maturation to form a functioning virion. The MA protein targets and binds to the plasma 
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membrane of the host cell, while NC proteins and CA proteins interact to encapsidate viral RNA, 
packaging the viral genome within the virion (Freed, 2001). MA also functions to recruit and 
localize Env proteins to the cell surface assembly sites through direct and indirect interactions 
(Checkley, Luttge, & Freed, 2011). The virus then pinches off from the host cell membrane to 
create an immature virion that is surrounded by a layer of cell membrane in a process called 
budding. Maturation of the virion is marked by proteolytic cleavage of polyproteins. The Gag 
protein is proteolyzed into MA, CA, NC, and p6 while the Env protein is broken down into 
surface or gp120 (SU) and transmembrane or gp41 (TM) proteins. The Pol polyprotein is broken 
down into protease (PR), RT, and IN (Frankel & Young, 1998).  Tat, Rev, Vpu, Vif, Vpr, and 
Nef are the six accessory proteins that have various functions. Figure 2 depicts all the viral 
polyproteins and accessory proteins, and their locations in the virion. The resulting mature virion 
has a membrane decorated with envelope proteins on the outside, matrix proteins on the inside, 
and holds a conical capsid made of CA proteins that stores the remaining viral proteins and two 
copies of viral RNA, as depicted in Figure 2. The resultant virion is capable of binding to a new 
host cell to resume the viral replication cycle.  
 
Uncoating  
            Capsid structure.  Uncoating is the disassembly of the viral capsid and is a required step 
of early HIV-1 infection that is not fully understood. The viral capsid is a conical structure 
composed of 1,000 to 1,500 CA protein monomers (Briggs et al., 2004). Capsid monomers have 
two domains, an N-terminal domain and a C-terminal domain. The CA protein is composed of 
predominantly alpha helices, with the C-terminal domain housing 4 alpha helices and the N-
terminal domain housing 6 alpha helices (Berthet-Colominas et al., 1999). CA monomers 
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polymerize to form many hexameric and some pentameric structures that constitute the viral 
capsid. The N-terminal domains typically form a rigid, 6-fold ring on the inside of the polymer 
while the C-terminal domains form a mobile outer belt that is capable of rotation in compliance 
with the inner N-terminal ring (Pornillos, Ganser-Pornillos, & Yeager, 2011). These hexameric 
polymers form a lattice that contains few pentameric structures that allow the structure to have 
curved edges. Although the typical shape of the capsid is conical, the capsid possesses 
morphological abilities and at times takes on a spherical or tubular shape (Li et al., 2016). The 
capsid encloses essential viral components for infection. Two copies of the viral RNA genome, 
NC, RT, IN, and viral accessory proteins are all found inside the capsid core (Accola, Öhagen, & 
Göttlinger, 2000). The capsid structure is an important component of viral uncoating. 
 Models of uncoating. The exact process by which the viral capsid uncoats has not been 
established. Three uncoating models exist to propose the method by which uncoating occurs, but 
it is possible that HIV-1 uncoats using different methods or a combination of methods when 
infecting different types of cells. The first suggested method of uncoating is rapid core 
disassembly in which once the virus enters the host cell, the capsid immediately falls apart. As 
reverse transcription takes place between viral entry and integration, RTCs were examined for 
viral proteins to attempt to determine the point at which the virus uncoats. The complexes were 
found to have high densities of MA, RT, and IN proteins and low densities of CA proteins 
(Fassati & Goff, 2001). From these data, it was concluded that the capsid core must rapidly 
dissociate following viral entry before the formation of the RTC. Since these studies, this first 
model has been largely discounted because CA protein has been detected in the cytoplasm 
associated with the RTC and the discovery of cellular factors, such as microtubules, that interact 
with the capsid (McDonald et al., 2002; Peng et al., 2014).  
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            The second model of uncoating suggests that the capsid core remains intact immediately 
following viral entry, and gradually disassembles in the cytoplasm during reverse transcription 
and transport of the RTC to the nucleus. This cytoplasmic uncoating model proposes that 
uncoating is promoted by several factors, including CA contact with cellular factors in the 
cytoplasm and molecular rearrangements that accompany reverse transcription. Evidence of this 
relationship between uncoating and reverse transcription was found when treatment with reverse 
transcription inhibitors delayed uncoating (Hulme, Perez, & Hope, 2011). Further studies have 
suggested that uncoating occurs after the first strand transfer of reverse transcription (Cosnefroy, 
Murray, & Bishop, 2016). These discoveries show that the steps of uncoating and reverse 
transcription may have some influence on each other, and since reverse transcription is a 
cytoplasmic event, the cytoplasmic model is plausible.   
           The nuclear pore complex model of uncoating suggests that the capsid remains intact until 
encountering the nuclear pore complex, where the intact capsid is too large to travel through the 
nuclear pore. Uncoating is thought to occur while the capsid is tethered at the nuclear pore 
complex and after the completion of reverse transcription. The mutation of CA protein, 
Q63/67A, was found to produce virial complexes that improperly uncoat and are defective in 
nuclear import and integration (Dismuke & Aiken, 2006). This link between capsid uncoating 
and nuclear import supports the nuclear pore complex model. Nuclear import proteins such as 
TNPO3 and NPC proteins have been found to influence the rate of uncoating, providing further 
evidence that uncoating occurs at the nuclear pores (Lee et al., 2010).  
            Viral and cellular factors. Uncoating is a complicated process that requires interactions 
from other steps of the viral replication cycle in order to occur. Previous studies have 
investigated the importance of CA structure in relation to the kinetics of uncoating of the viral 
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capsid. Mutant A92E was found to significantly increase the rate of uncoating while mutants 
E45A and N74D delayed the rate of uncoating (Hulme, Kelley, Okocha, & Hope, 2015). Mutant 
A92E has a mutation in CypA binding loop in CA, and successfully infects cells when CypA is 
inhibited (Qui, Yang, & Aiken, 2008). This mutant explores the relationship between CypA and 
CA, and how that relationship affects viral infectivity. Mutant E45A has a mutation in Helix 2 of 
CA (Yamashita, Perez, Hope, & Emerman, 2007).  This mutant does not have the same 
dependence on TNPO3 and NPC proteins that wildtype HIV does (Lee et al., 2010). Mutant 
N74D uses a different pathway for nuclear import, utilizing NUP155 instead of NUP153 (Lee et 
al., 2010). This type of mutation allows investigation of cellular factors required for nuclear 
import of HIV-1. All of these capsid mutants alter the kinetics of uncoating and consequently 
decrease overall viral infectivity (Forshey, von Schwedler, Sundquist, & Aiken, 2002; Hulme et 
al., 2015; von Schwelder, Stray, Garrus, & Sunquist, 2003).  
            The uncoating of the capsid core is a complex step of viral infection that may require the 
involvement of other steps of viral infection, including reverse transcription and integration. As 
previously discussed in the cytoplasmic uncoating model, there is a relationship between reverse 
transcription and uncoating. Additionally, some models suggest that as reverse transcription 
progresses and flexible RNA is converted into more rigid double stranded DNA, the capsid core 
must remodel to accommodate this change (Campbell & Hope, 2015).  Integrase is the viral 
protein that integrates the viral genome into host DNA. This viral enzyme was found to interact 
with the viral core. A study introduced mutations to IN and observed a decrease in viral capsid 
core yield and stability (Briones, Dobard, & Chow, 2010). Thus, it is possible that IN helps 
stabilize the capsid core. Furthermore, mutations in IN resulted in virions depleted of the cellular 
protein Cyclophilin A (CypA) that produced unstable viral capsid cores (Briones et al., 2010). 
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These discoveries suggest that integrase and CypA interaction may have an effect on capsid core 
stability.  
            CypA is an important cellular molecule when discussing uncoating as it binds to CA to 
potentially affect uncoating. CypA binds directly to the N terminal domain of the capsid core 
(CANTD) via a Gly89-Pro90 peptide bond, and functions to catalyze the cis/trans isomerization of 
the peptide bond (Bosco, Eisenmesser, Pochapsky, Sundquist, & Kern, 2002). The isomerization 
results in a conformational change of the CANTD but the effect that CypA binding to CA has on 
uncoating varies. Recent experiments investigating this have found conflicting results, 
concluding that CypA destabilizes the HIV-1 capsid core, CypA stabilizes the core to inhibit 
HIV-1 uncoating, and, in some cell types, CypA does not affect HIV infectivity (Fricke, 
Brandariz-Nuñez, Wang, Smith, & Diaz-Griffero, 2013; Hatziioannou, Perez-Caballero, Cowan, 
& Bieniasz, 2005; Shah et al., 2013). Regardless, it is noted that CypA is an important variable in 
HIV-1 uncoating and further research on this cellular factor is needed.  
            The breakdown of the nuclear envelope is not necessary for HIV-1 to establish infection 
in cells, meaning that HIV-1 can infect non-diving cells.  Virus enters the nucleus by capsid 
proteins interacting with various cellular proteins including CPSF6, TNPO3, and NPC proteins. 
CPSF6 is a cellular protein that shuttles between the nucleus and cytoplasm, and colocalizes with 
the RTC in the cytoplasm to aid in nuclear import (Peng et al., 2014). CPSF6 interacts with HIV-
1 CA protein in the binding pocket formed between neighboring CANTD and CACTD 
(Bhattacharya et al., 2014). This protein contains a Serine/Arginine rich nuclear localization 
signal (NLS) on its C terminus that, when removed in mutant CPSF61-358, inhibits HIV-1 
infection by a defect in nuclear entry (Lee et al., 2010; Peng et al., 2014). This protein plays a 
large role in nuclear entry of HIV-1 by interaction with CA protein but is not the only key player. 
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TNPO3 is a protein that transports cargo into the nucleus and influences the nuclear localization 
of CPSF6 (Kataoka, Bachorik, & Dreyfuss, 1999). Because infectivity of HIV-1 is inhibited by 
knockdown of TNPO3, it is thought that TNPO3 is involved in nuclear import (Lee et al., 2010). 
This influence on nuclear import may be indirect by interaction with CPSF6, or straightforward 
by TNPO3 directly binding to the HIV-1 CA (Zhou et al., 2011).  
            NPC proteins are also of interest when discussing nuclear import. Two NPC proteins in 
particular, NUP358 and NUP153, were found to be cellular factors required for HIV-1 infection 
(Brass et al., 2008). NUP358, also referred to as RanBP2, is a protein that protrudes from the 
NPC into the cytoplasm of the cell and is involved in various nucleo-cytosplasmic transport 
pathways (Zhang, Mehla, & Chauhan, 2010). This NPC protein has a CypA homology domain 
that interacts with viral capsid protein (Schaller et al., 2011). Although this interaction has been 
discovered, the exact mechanism in which these proteins interact is still under investigation. 
NUP153 is a part of the NPC that has filaments extended into the nucleoplasm, instead of the 
cytoplasm (Strambio-De-Castilla, Niepel, & Rout, 2010). CA also interacts with NUP153 to aid 
in nuclear import (Price et al., 2012). These findings suggest that CA interaction with NPC 
proteins is necessary for nuclear import of the RTC, and due to this interaction, NPC proteins 
may play a role in uncoating.  
            Other cellular factors involved in uncoating are microtubules and motor proteins. 
Disruption of microtubules, dynein, dynein heavy chain 1 (DYNC1HC1), and KIF5B delays 
uncoating (Lukic, Dharan, Fricke, Diaz-Griffero, & Campbell, 2014). KIF5B of the Kinesin-1 
family may be involved in both uncoating and nuclear import. An interaction dependent on both 
KIF5B and the viral capsid results in NUP358 relocation from the NPC to the cytoplasm (Dharan 
et al., 2016). This interaction may directly or indirectly influence uncoating and nuclear import. 
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Microtubule associated proteins have also been found to have influence on steps of HIV-1 
infection. The dynein adapter protein Bicaudal D2 (BICD2) binds the viral capsid and mediates 
trafficking of the viral complex, and depletion of this protein inhibits uncoating (Dharan et al., 
2017).  It is also thought that HIV-1 exploits the functions of diaphanous-related formins 
(DRFs), which manage actin nucleation and microtubule stabilization, to coordinate uncoating 
and control microtubule stabilization for virus transport (Delaney, Malikov, Chai, Zhao, & 
Naghavi, 2017). It is probable that other microtubule associated proteins (MAPs) that function in 
the same way as DRFs are also involved in capsid interaction for viral complex trafficking and 
uncoating.  
            There are two models that propose the mechanism of interaction between microtubules 
and motor proteins with the capsid. The tug of war model suggests that kinesin and dynein pull 
the capsid apart concurrently (Gaudin, de Alencar, Arhel, & Benaroch, 2013). The NPC- and 
kinesin-mediated uncoating model suggests that dynein chaperones the capsid core to the nuclear 
pore complex, where interaction between the capsid and NPC directly induces uncoating 
(Campbell & Hope, 2015) or interaction at the NPC anchors the capsid while kinesin provides 
the force necessary for uncoating (Campbell & Hope, 2015). The exact method of interaction 
between HIV-1 capsid and microtubules and motor proteins is still under debate, but it can be 
agreed upon that they are essential factors in the viral replication process.  
            To determine how cellular factors affect uncoating, the kinetics of uncoating were 
compared in OMK cells and HeLa cells.  The uncoating of wildtype virus occurred faster in 
HeLa cells than in OMK cells while the N74D mutant had a longer delay of uncoating in HeLa 
cells, possibly due to a factor that is present in more abundance in one cell line than another 
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(Hulme et al., 2015). Because that factor(s) remains unknown, the effect of differences in cellular 
environments on uncoating is an area of interest that is worth further researching. 
 
Microglial Cells 
As the resident macrophage of the brain, microglial cells are important for maintaining 
the health of the central nervous system. Microglial cells serve an immune surveillance function 
while at rest by continuously sampling their environment with highly motile protrusions and 
sensing changes through surface receptors, such as receptors for complement fragments, 
immunoglobulins, adhesion molecules, and inflammatory stimuli (Nimmerjahn, Kirchhoff, & 
Helmchen, 2005). When signs of infection or injury are discovered, the microglial cells rapidly 
convert to an active state and release molecules to begin an immune response. These molecules 
are pro-inflammatory mediators and include cytokines, chemokines, reactive oxygen species 
(ROS), and nitric oxide (Saijo & Glass, 2011). The release of these molecules promotes 
inflammation and is intended to isolate the infectious agent to prevent further contact with body 
tissues. However, when pro-inflammatory molecules are released excessively by microglial cells 
pathological forms of inflammation may result and contribute to neurodegenerative disease 
(Saijo & Glass, 2011). Therefore, microglial cells play a large role in protecting the CNS from 
infection but can also be detrimental when they are inappropriately activated. 
HIV infection of microglial cells are linked to HIV-associated neurological disorders 
(HAND) found in HIV/AIDS patients. HAND is an area of interest due to its negative effects on 
brain function. Three subcategories of HAND exist to categorize the degree of neurological 
impairment caused by HIV infection. Asymptomatic neurocognitive impairment (ANI) is 
classified by abnormality in two or more cognitive abilities with no functional impairment, while 
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mild neurocognitive disorder (MND) is cognitive impairment with mild functional impairment 
(Elbirt et al., 2015). The most serious of the three subcategories is HIV-associated dementia 
(HAD). HAD is classified as marked cognitive impairment with marked functional impairment 
(Elbirt et al., 2015). The mechanism by which HIV infections causes HAND is still unknown.   
HIV infects cells that express CD4 receptors such as T-cells, macrophages, and dendritic 
cells, as well as microglial cells. HIV cannot cross the blood brain barrier, so it does not directly 
infect the brain but enters the brain by infecting migrating monocytes and lymphocytes that cross 
the blood brain barrier (BBB) (Elbirt et al., 2015). Once inside the brain, infected monocytes 
transform into macrophages and microglial cells. The infection is spread throughout the brain by 
cells from the macrophage lineage. Macrophages and microglial cells express neurotoxic 
molecules that activate astrocytes, leading to increased BBB permeability (Elbirt et al., 2015). 
Infected monocytes and lymphocytes migrate across the BBB easier with increased permeability 
and continue to spread the infection. Although microglial cells are not primarily infected by HIV 
in the CNS, once infected cells migrate into the CNS and differentiate into several types of 
macrophages, microglial cells become infected and play a role in spreading the infection 
throughout the brain. 
Two models exist that hypothesize how HIV positive cells cause neurodegeneration. The 
first model is a direct model that states HIV infected monocyte-derived cells release viral 
proteins gp120, Tat, and Vpr that interact directly with neurons causing neuronal death (Elbirt et 
al., 2015). The direct model suggests that microglial cells, along with other monocyte-derived 
cells, interact firsthand with neurons. The indirect model hypothesizes that neuronal death is 
caused by the inflammatory response against HIV infection and HIV proteins released by 
directly infected cells (Elbirt et al., 2015). While the direct model blames physical contact 
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between viral proteins and neurons for neuronal death, the indirect model blames the 
overwhelming inflammatory response to HIV infection. While the exact method of neuronal 
death leading to HAND is unknown, the importance of studying the details of HIV infection in 
microglial cells remains.   The study of uncoating in microglial cells will uncover more in-depth 
information about early infection in the central nervous system that eventually leads to HAND. 
Highly active antiretroviral therapy (HAART) is the current therapy method used to treat 
patients with HIV and, when the treatment is strictly adhered to, is effective at keeping the 
infection minimal and below levels of detection. One reason it is thought that HAART is unable 
to completely eliminate the virus from an infected individual is the difficulty to reach latently 
infected cells in viral reservoirs. A viral reservoir is a cell or an anatomical site in association 
with which a replication-competent form of the virus accumulates, meaning it is able to replenish 
the population of infected cells and is not defective, and persists with more stable kinetic 
properties than in the main pool of actively replicating virus (Blankson, Persaud, & Siliciano, 
2002). Viral reservoirs ensure that the virus is able to maintain infection throughout the body by 
providing an escape from immune response efforts. There are two different types of latency that 
occurs in reservoirs. “Pre-integrated latency” occurs when the pre-integration complex (PIC) 
exists in the cytoplasm of an infected cell (Lambotte, Deiva, & Tardieu, 2006). Cells with pre-
integrated latency could be active or inactive, and eventually the pre-integration complex will 
migrate from the cytoplasm into the nucleus to integrate itself into the cellular DNA and produce 
virions to spread the infection. The second type of latency is “post-integrated latency” in which 
the linear viral DNA complex, or PIC, is integrated into the cellular DNA of inactive cells, and 
when the cell becomes active later on, the integrated viral form is transcribed, and viral RNA is 
produced allowing the production of new virions (Lambottee et al., 2006). Reservoir cells are 
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latently infected by HIV and contribute to the persistence of infection despite the efforts of drug 
treatment. The major reservoir cells in CNS are microglia, perivascular macrophages, and 
astrocytes (Garcia-Mesa et al., 2017).  It is important to study the early steps of HIV infection in 
microglial cells because they are a subtype of latent cells located in the viral reservoir in the 
brain.  
Immortalized primary microglial cells isolated from human brain tissue are ideal to use 
while studying HIV infection in microglial cells. The use of this cell line, called C20, ensures 
that data collected closely resembles what actually happens when HIV infects the human brain. 
Many previous HIV investigations are conducted using cells that are not naturally infected by 
HIV. This can be problematic as cell to cell protein variability may impact the pathology of HIV 
infection, making the data potentially misleading. C20 cells are immortalized cells that originate 
from human cortical brain tissue obtained from adults undergoing brain surgery at University 
Hospitals of Cleveland (Garcia-Mesa et al., 2017). Primary microglial cells are delicate and 
difficult to maintain in culture, so the cells were immortalized to allow experimentation. To 
immortalize, the primary microglial cells were infected with vesicular stomatitis virus G 
enveloped simian virus 40 (VSVG SV40) expressing large T antigen and selected in the presence 
of 2 ug/mL of puromycin. The cells were then superinfected with VSVG hTERT-neomycin viral 
particles to express human telomerase reverse transcriptase and antibiotic-resistant colonies were 
selected in the presence of 2 ug/ml puromycin and 600 ug/ml neomycin (Garcia-Mesa et al., 
2017). Once the cells were immortalized, characterization took place. It was confirmed that the 
C20 cells were of human origin using PCR amplification of the human CYCT1 gene from DNA 
isolated from the immortalized human microglial cells (Garcia-Mesa et al., 2017).  Confirmation 
of the species of origin is an important step in ensuring that the cells will provide the most 
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accurate data. Upon characterization, it was found that the C20 cells express key microglial 
surface markers, have microglial-like morphology, demonstrate appropriate migratory and 
phagocytic activity, and have the capacity to mount an inflammatory response characteristic of 
primary microglia (Garcia-Mesa et al., 2017).  These characteristics, especially cell signaling, 
demonstrate how the C20 cell line is a close representation of real microglial cells and, therefore, 
is an ideal cell line to use to investigate HIV infection in the CNS.  
 
TRIM-CypA and CsA Washout Assay  
TRIM5 and TRIM-CypA are a part of the TRIM5 family of proteins that act as 
restriction factors to retroviruses. TRIM5 proteins exist in nature in different isoforms.  TRIM5 
is composed of RING, B-box, coiled-coil, and SPRY domains (Li et al., 2016). A related TRIM 
protein named TRIM5-Cyclophilin A (TRIM-CypA) is expressed in owl monkeys by a 
retrotransposition of Cyclophilin A (CypA) into TRIM5 intron 7 (Nisole, Lynch, Stoye, & Yap, 
2004). The CypA domain exits on the TRIM-CypA protein where the SPRY domain exists on 
the TRIM5 (Li et al., 2016). Aside from the difference in one prominent domain, TRIM5 and 
TRIM-CypA are similar proteins. Their sizes are comparable with TRIM5 being 55 to 60 kDa 
and TRIM-CypA being 45 kDa (Nepveu-Traversy, Bérubé, & Berthoux, 2009). TRIM5 proteins 
have the ability to bind to the capsid of incoming retroviruses, such as HIV, to restrict infection. 
In the TRIM-CypA form of the TRIM5 protein, the CypA domain acts to bind to viral capsid 
proteins. This interaction occurs via flexible loops on the CypA domain and allows TRIM-CypA 
to form a hexagonal net on the viral capsid to act as a restriction factor (Li et al., 2016).  The 
restrictive properties of TRIM-CypA are utilized in research to better understand characteristics 
of the HIV capsid.  
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Cyclosporin A (CsA) is a drug that binds to TRIM-CypA and inhibits its function. Thus, 
in the presence of CsA, uncoating of the HIV capsid can occur and the virus establishes infection 
(Figure 3). The CsA washout assay is an infection assays done in the presence of CsA with cells 
that contain TRIM-CypA and are used to study the rate of uncoating. In these assays, CsA is 
washed out at different timepoints and the amount of uncoating of that virus can be determined at 
specific timepoints by measuring infectivity. To be resistant to TRIM restriction, a virus would 
have to have already uncoated at the time when CsA is washed out. Flow cytometry is used to 
determine infectivity by percentage of GFP positive cells. Cells that express GFP have 
completed the step of uncoating, therefore providing a method to determine the amount of 
uncoating at a specific timepoint. A control washout is done using ethanol in place of CsA.  
Previous uncoating studies done in OMK and HeLa cells have utilized the CsA washout 
assay. OMK cells naturally express TRIM-CypA while HeLa cells in this experiment were 
engineered to express TRIM-CypA. Parallel CsA washout assays found that HIV-GFP uncoated 
significantly faster in HeLa cells than in OMK cells (Hulme et al., 2015). Variability of cellular 
proteins in OMK and HeLa cells is thought to be the explanation of the difference in uncoating 
kinetics between the two cell lines because HIV uses cellular factors to establish infection.  
            There are multiple assays in the field used to study uncoating. The in situ uncoating assay 
uses dual labeled virus with GFP-Vpr to detect virions and S15-mCherry labeled viral membrane 
that is lost upon viral fusion (Campbell, Perez, Melar, & Hope, 2007). At various points of 
infection, cells are fixed and stained for CA protein to determine whether uncoating has occurred 
(Campbell et al., 2007). The fate of capsid assay is another method used to study uncoating. This 
assay fixes cells at various timepoints postinfection, uses ultracentrifugation, and cell extracts are 
18 
examined for the separation of soluble capsid protein from capsid cores (Yang, Luban, & Diaz-
Griffero, 2014).  
            The CsA washout assay was used in this study because of its many benefits. The CsA 
washout assay is beneficial because it removes any virus that uncoats that is not replication 
competent from the data because the read out is GFP positive infected cells. In situ uncoating 
assays and fate of capsid assays do not remove replication incompetent virus because they test 
for capsid protein to determine if uncoating has occurred and are not selective for capsid in virus 
that is replication competent. The usage of TRIM-CypA in this assay is beneficial because the 
protein binds directly to the capsid and restricts uncoating directly. The entire CsA uncoating 
assay is done in live cells, allowing infectivity to run its course before cells are fixed while in 
situ uncoating assays and fate of capsid assays fix cells at various timepoints post-infection. 
Often the fate of capsid assay work is done past when uncoating occurs. The in vivo aspect of 
this assay provides data that is similar to what happens in the human body which is useful in 
developing a vaccine or cure.   
 
Hypothesis and Aims 
The goal of this project is to characterize the kinetics of HIV-1 uncoating in C20 
microglial cells. This research question is relevant because neither OMK cells nor HeLa cells are 
among the types of cells infected by HIV-1 in the human body, while C20 cells are. Cellular 
proteins differ in each cell line which is relevant to HIV-1 infection because the virus utilizes 
cellular factors to establish infection. Research conducted in non-naturally infected cells may 
confer results that differ from naturally infected cells. Thus, it is essential to study the kinetics of 
early infection in cells such as microglial cells that are infected by HIV-1 in the human body. I 
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hypothesize that C20 microglial cells will have a faster rate of uncoating when infected with 
HIV-GFP in comparison to OMK cells and HeLa cells, with uncoating kinetics being more 
similar to HeLa cells because they are a human cell line. To test this hypothesis, three aims were 
proposed. The first aim was to characterize the effect of CsA on HIV-1 infectivity in C20 cells 
and the timing of viral fusion. The second aim was to establish a C20 cells that stably expresses 
TRIM-CypA. The third aim was to determine uncoating kinetics of wild type HIV-1 in the 
established C20-TRIM-CypA cell line. 
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Figure 1. Early steps of the HIV-1 replication cycle. This image was obtained from “HIV-1 
capsid: the multifaceted key player in HIV-1 infection” (Campbell & Hope, 2015). 
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Figure 2. HIV-1 polyproteins and accessory proteins in the viral genome. This image was 
obtained from “HIV-1: fifteen proteins and an RNA” (Frankel & Young, 1998). 
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Figure 3. The interactions behind the CsA washout assay. Interaction of CsA with TRIM-CypA 
inhibits the protein and diminishes the restriction of HIV-1 infection. This image was obtained 
from “The CsA washout assay to detect HIV-1 uncoating in infected cells” (Hulme & Hope, 
2014).  
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MATERIALS AND METHODS 
 
 
Maintain and Culture Cell Lines 
            The use of cells in this project did not require Institutional Review Board approval. The 
293T cell line utilized to make HIV-GFP is a human embryonic kidney cell line obtained from 
American Type Culture Collection. The CHME3 cell line is a human microglial cell line and the 
TCN14 cell line is CHME3 cells engineered to express TRIM-CypA, and both cell lines were 
obtained from the Naghavi Lab at Northwestern University (Janabi, Peudenier, Héron, Ng, & 
Tardieu, 1995).  The C20 cell line is a human microglial cell line obtained from Karn Lab at 
Case Western Reserve University (Garcia-Mesa et al., 2017). All cultured cell lines used were 
adherent cells that were grown in plastic 10 cm tissue culture dishes. Cells were grown in an 
incubator set at 37C with the presence of 5% CO2. All experiments involving cells were done in 
a tissue culture hood with the use of sterile technique.  The media used for 293T cells was 
Dulbecco’s Modified Eagle Media (DMEM; Corning) with the addition of 10% fetal bovine 
serum (FBS; Atlanta Biological), 100 U/ml penicillin streptomycin (Corning), and 292 µg/ml L-
gutamine (PSG; Corning). C20 and C2-9 microglial cells used DMEM media with 5% FBS, 100 
U/ml penicillin streptomycin, 292 µg/ml PSG, and 1% Sodium Pyruvate (Corning). Media used 
for C2-9 cells also contained 100 µg/ml of hygromycin B (Corning).  
            Cells adhered to the bottom of the plate and when they grew to confluency, they had to be 
split in order to continue actively growing. The 293T cells and the C20 cells and C2-9 cells were 
split using different methods. To split 293T cells, media and trypsin (Corning) were warmed in a 
37C water bath before media was aspirated from the tissue culture plate and 1 ml of trypsin was 
carefully added to the plate. After washing the cells in trypsin, the trypsin was aspirated from the 
plate and the plate was placed in the 37C incubator for approximately 2 minutes. Following 
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incubation, 10 ml of media was added to the plate to inactivate the trypsin. The cells were 
resuspended and 1 ml of the cell suspension was transferred to a new 10 cm plate containing 10 
ml of fresh media. The plate was gently rocked and then placed in the 37C incubator. Cells were 
observed under a microscope daily and split every 2 to 3 days.  
            To split the C20 and C2-9 microglial cell lines, the media and trypsin was warmed in a 
37C water bath, the media was aspirated from the 10 cm plate containing the cells, and 5 ml 1X 
phosphate-buffered saline (PBS; Corning) was added to the plate to wash away any residual 
media. The PBS was aspirated and 3 ml of trypsin was added before the plate was put into the 
37C incubator for 2 to 3 minutes. Following incubation, 7 ml of media was added to the plate to 
inactivate the trypsin and resuspend the cells. A new 10 cm plate was prepared with 10 ml of 
fresh media and 2 ml of the cell suspension was transferred to the new plate and stored in the 
37C incubator. The cells were observed daily and split every 3 to 4 days.  
At times when cells were to be left unattended for long periods of time or to retain a 
stock, it was necessary to freeze cell lines. To freeze cells, a freeze media was first made. This 
consists of 4 ml C20 media, 500 dimethyl sulfoxide (DMSO; Sigma Aldrich), and 500 µl of 
FBS.  The cells were split into a 15 ml conical tube and spun at 1,000 x g at 4C for 3 minutes. 
The media was removed without disturbing the pellet and the pellet was resuspended in 2 ml 
freeze media and 1 ml of the solution was aliquoted into two cryovials. The vials were placed in 
a Nalgene Cryo Freezing Container and stored at -80C.  
Cells were thawed from the frozen stock stored at -80C. To thaw cells that were frozen 
down from a 6 well plate, a new 6 well plate was prepared by adding 3 ml of warm media to 
each well. The cryovial containing the frozen cells was held in a warm water beaker until it 
thawed. The 1ml of cells in the vial was slowly transferred to the 6 well plate. The plate was 
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incubated for 3 hours, then the media was removed and replaced with 4 ml of fresh media. Two 
days later, media with antibiotic was added. To thaw cells that were frozen down from a 10 cm 
plate, the cryovial containing the cells was held in a warm water beak until it thawed. The 1 ml 
of cells in the tube was transferred to a 15 ml tube and 10 ml of media was slowly added to the 
tube. Next, 11 ml from the tube was slowly transferred to a 10 cm plate and then 5ml of fresh 
media was added. The plate was incubated for 3 hours and then the media was removed and 
replaced with 15 ml of fresh media.  
 
HIV-GFP Virus Production 
            HIV-GFP is a single round virus made from two plasmids, the viral genome plasmid with 
a mutated envelope gene and GFP, and a vesicular stomatitis virus (VSV-G) envelope plasmid. 
The genome plasmid is a source of viral RNA and viral proteins, with the exception of envelope 
protein. The envelope plasmid encodes for the VSV-G envelope protein, which allows the virus 
to enter any kind of cell via endocytosis. The use of 2 plasmids create a single round vector, 
enabling the virus to only infect a cell once and preventing it from making more virus in that cell 
due to the mutated envelope protein. This makes HIV-GFP a replication defective virus.  
            A polyethylenimine (PEI) transfection of 293T cells was used to make HIV-GFP virus. 
To begin, 293T cells were seeded into a 10 cm plate so that they would be 80-90% confluent on 
the day of transfection. A transfection mixture was made containing 1 ml DMEM, 6 µg HIV-
GFP proviral plasmid, 4 µg CMV-VSV-g plasmid, and 40 µl PEI (Polysciences). The mixture 
was incubated at room temperature before being added in a dropwise manner to the media of a 
10 cm dish containing 293T cells. The dish was then incubated for 24 hours. The media was 
aspirated from the 10 cm dish and replaced with 10 ml of fresh, warmed media, and the cells 
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were then incubated for 16-18 hours. The media containing virus was then transferred from the 
10 cm dish to a 15 ml conical tube using a serological pipet. The virus was then filtered using a 
syringe attached to a 0.45 um filter. The virus was stored at -80C in 1 ml aliquots in cryovials.  
 
TCSH Virus Production 
            To engineer a cell line that expresses TRIM-CypA, a virus was made that contains genes 
for the TRIM-CypA (TC) protein and hygromycin (H) resistance (TCSH). To make TCSH virus, 
a PEI transfection of 293T cells was done. C20 cells were plated in 8 wells of a 12 well plate to 
be 80-90% confluent on the day of transfection. A mixture containing 200 µl of DMEM, 4 µg of 
pLXSN-TRIMCypa (TCSH) plasmid (Mamede, Sitbon, Battini, & Courgnaud, 2014), 4 µg of 
VSV-g plasmid, and 8 µl of PEI was combined and incubated at room temperature for 15 
minutes. To each well, 104 µl of the transfection mixture was added in a dropwise manner. The 
plate was then incubated for 24 hours. The media was aspirated from the plate and replaced with 
1 ml of fresh, warmed media per well, and the cells were then incubated for 16-18 hours. The 
media containing virus was then transferred from the 12 well plate to a 15 ml conical tube using 
a serological pipet. The virus was then filtered using a syringe attached to a 0.45 um filter. The 
virus was stored at -80C in 1 ml aliquots in cryovials. 
 
Hygromycin Kill Curve 
            A hygromycin kill curve was established to determine the concentration of hygromycin B 
needed to kill C20 cells that did not contain the gene for hygromycin resistance. C20 cells were 
plated in a 6 well plate. A different concentration of hygromycin B in media was added in each 
well (Table 1). The first run of this experiment used concentrations of 0 µg/ml, 100 µg/ml, 200 
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µg/ml, 300 µg/ml and 400 µg/ml and the cells were observed for 6 days. To better clarify which 
concentration of hygromycin would be optimal for selection of cells, the experiment was 
repeated a second time with lower concentrations including 0 µg/ml, 50 µg/ml, 100 µg/ml, 150 
µg/ml, and 200 µg/ml. The cells were observed to determine which concentration killed all cells 
in a reasonable amount of time. 
 
C2-9 Cell Line Production 
            Figure 4 is a summary of the process of establishing the C2-9 cell line. The C20 cells 
infected with different dilutions of TCSH, ½ dilution, ¼ dilution, 1/8 dilution, 1/16 dilution, 1/16 
dilution, and no virus as a control, in a 6 well plate. The day after infection, the media was 
replaced with warm C20 media. Two days after infection, the media was replaced with C20 
media containing hygromycin B that was at a concentration determined by the hygromycin kill 
curve method. In the 6 well plate, one well containing cells infected with a 1/16 dilution of 
TCSH received media without drug to serve as a control. Antibiotic selection continued until all 
cells had died in the no virus control well.  The cells in the 6 well plate in the ¼ and ½ dilution 
were maintained until they were confluent and healthy enough to split to a 10cm plate. The C20 
cells infected with ½ dilution of TCSH and ¼ dilution of TCSH were split into 10cm plates. 
Once confluent, cells from each dilution were frozen down while others were kept in culture.  
The cells were counted and diluted to 1 cell/600 µl and plated on 96 well plates in 
attempt to isolate colonies. This method failed to produce viable colonies and a new approach 
was taken. The C20 cells infected with ¼ dilution of TCSH were thawed and grown in culture. 
The cells were counted, and a series of dilutions were made to achieve four dilutions of cells on 
four 10cm plates: 100 cells/plate, 75 cells/plate, 50 cells/plate, and 25 cells/plate. The cells were 
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allowed to grow for 18 days before 8 colonies were picked from the 100 cells/plate diluted plate 
and for 21 days before 12 colonies were picked from the 75 cells/plate diluted plate.  
To isolate clones, individual colonies had to be lifted off of the plate. Pieces of filter 
paper were autoclaved and soaked in 1 ml of trypsin in a 6 well plate. Tweezers were used to 
place individual pieces of filter paper on each colony and lift. The filter paper with the colonies 
was placed in a 24 well plate with 1ml of C20 media. The cells were allowed to grow in the 24 
well plates for 3 days before the filter paper was removed and the media was replaced with C20 
media containing hygromycin B.   
The cells remained under antibiotic selection as they were grown and spilt as depicted by 
Figure 5. From the 24 well plate the cells were transferred to a 12 well plate. Once cells were 
confluent in the 12 well plate, the cells were split to prepare a whole cell lysate for western blot 
as described in the western blot methods section, and the remainder of cells were plated in a new 
12 well plate. Once confluent, the cells were split into a 6 well plate until confluent then frozen 
and stored at -80C.  
 
Western Blot 
To confirm presence of the TRIM-CypA protein in the new cell lines, a western blot was 
performed with an antibody targeted to the HA tag on TRIM-CypA. A whole cell lysate was 
produced from each cell line. Cells were lysed by adding 200 µl of 1X Laemmli Sample Buffer 
(Bio-Rad) containing -mercaptoethanol (Fischer Scientific) to a confluent well of cells in a 12 
well plate. The cells became viscous as they lysed, and the lysate was transferred to an 
Eppendorf tube. This cell lysate was then boiled at 100C for 3 minutes, cooled, and centrifuged 
for 20 seconds at full speed. The samples were stored at -20C until ready for use. 10% Tris-HCl 
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Bio-Rad Ready Gels (Bio-Rad) were assembled in a Bio-Rad gel rid according to the 
manufacturer’s instructions and 12 µl of an all blue standard protein ladder (Bio-Rad) was 
loaded into the first well. Protein samples were boiled at 100C for 5 minutes, and then 40 µl of 
each sample was loaded onto the gel. The gel was run at 200 V for 40 minutes.  
Following electrophoresis, the proteins and ladder were transferred from the gel to a 
membrane using a Bio-Rad Transblot Semi-Dry Electrophoretic Transfer Cell. The membrane 
was pre-wet in dH2O for 2 minutes, then soaked in Towbin Transfer buffer for 45 minutes. When 
the gel finished running, it was removed from the cassette, rinsed in dH2O, and equilibrated in 
transfer buffer for 30 minutes. Extra thick filter paper was also soaked in transfer buffer. The 
transfer sandwich was assembled in the following order- filter paper, gel, membrane, filter paper, 
and then flipped. The gel was then transferred at 15 V for 35 minutes.  
Following transfer, the membrane was rinsed in dH2O and blocked in 10 ml of 3% low-
fat powdered milk in TBS for 1 hour. The membrane was then rinsed with two changes of 1X 
TBS-T, and then washed with 1X TBS-T for 5 minutes. The blot was exposed to the primary 
anti-HA rat 3F10 antibody (Roche Diagnostics) a 1:2000x in 3% Fraction V (Fischer 
Scientific)/TBS-T, overnight at 4C.  
Two brief rinses of TBS-T were performed followed by three washes with TBS-T for 5 
minutes each. The anti-rat HA secondary antibody was diluted in 3% low-fat powdered 
milk/TBS and added to the membrane in a small container. The membrane was incubated for 1 
hour. Next, the membrane was washed with two brief rinses of TBS-T and three washes with 
TBS-T for 5 minutes each. To visualize the membrane, the SuperSignal West Dura Extended 
Duration Substrate system (ThermoFischer) was used to detect chemiluminescence of 
horseradish peroxidase (HRP). On a piece of Saran wrap, 500 µl of SuperSignal West Dura 
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Stable Peroxide Buffer (ThermoFischer) was mixed with 500 µl of SuperSignal West Dura 
Luminol/ Enhancer Solution (ThermoFischer). The membrane was placed on the enhanced 
chemiluminescent (ECL) substrates for 5 minutes. Then, the membrane was wrapped in a fresh 
piece of Saran wrap. In a dark room, the membrane wrapped in Saran wrap was placed on a 
piece of film for 1 minute and developed. The membrane was placed on a second piece of film 
for 10 days and then developed.  
 
Test for Infectivity and Virus Titration 
            This method can also be used as a virus titration to determine the amount of virus to use 
for certain assays. From an 80-90% confluent plate, cells were split onto a new petri plate as 
normal and the remaining cell/media mixture was placed into a 15 ml conical vial. A Bright-Line 
1475 hemocytometer (Hausser Scientific) was used to determine cell count. Before use, the 
Hemocytometer was cleaned using a KIM Wipe and ethanol. Under the tissue culture hood, a 
glass cover slip was placed on top of the hemocytometer and 15 µl of cells were added. The 
hemocytometer was focused under a microscope and the number of cells in two 4X4 sections 
was counted separately and recorded. A concentration of 7,500 cells/well was calculated and 
cells were plated in a 96 well plate. For each virus tested, at least 6 wells of a 96 well plate were 
used and 3 wells of uninfected cells in cell culture media served as a negative control for flow 
cytometry. To each well, 100 µl of cells and media was added, using cell culture media to bring 
the cell mixture to the total volume. The calculated number of cells and media was added to a 15 
ml conical tube, and a multichannel micropipette was used to add 100 µl of the cell mixture to 
each well. The 96 well plate was then labeled with initials, virus name, and date, and placed in 
the 37C incubator overnight. 
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            To aid in infecting cells, 1X polybrene (Santa Cruz Biotechnology) media was made in a 
15 ml conical tube and 2X polybrene media was made in an Eppendorf tube. All media was 
aspirated from the 96 well plate, and 100 µl of 1X media was added to every well except H1 and 
H2 (see Figure 6), which had 100 µl of 2X media added. To H1, 100 µl of HIV-GFP virus was 
added and, to H2, 100 µl of positive control virus was added. Nothing was added to H3 as it was 
the negative control. The multichannel micropipette was used to mix the media and virus in H1 
and H2 by carefully pipetting up and down 3 times to create a ½ dilution of the original sample 
of virus. Next, 100 µl was transferred from H1/H2 to G1/G2 and mixed with the media in the 
wells by pipetting up and down 3 times to make a ¼ dilution. The serial dilution was continued 
by transferring 100 µl to each subsequent well and mixing each well by pipetting up and down 3 
times. The 100 µl from the last set of wells was discarded in bleach solution and the 96 well 
plate was placed in the 37C incubator overnight.  
            Media was aspirated from all of the wells and replaced with 200 µl of fresh media. The 
plate was then placed in the 37C incubator overnight. All of the media was aspirated from the 
96 well plate and 100 µl of trypsin was added to each well. The plate was incubated at 37C for 
3-5 minutes. The cells were viewed under a microscope to determine if they appeared to be 
“peeling up”, and the 96 well plate was lightly tapped to help loosen cells. The cell/trypsin 
mixture was resuspended in each well using a multichannel pipette, and 100 µl of 2% 
paraformaldehyde (Santa Cruz Biotechnology) was added to each well. The plate was wrapped 
in parafilm and aluminum foil and incubated at 4C overnight. The fixed samples were then run 
on a C6 Accuri flow cytometer with detector (laser) FL1 (488), standard filter (533/30 BP), and 
GFP fluorochrome with run limits of 10,000 events or 80 ul and fluidics set at fast. for GFP to 
determine the percentage of infected cells. 
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CsA Washout Assay 
To study the kinetics of viral capsid uncoating, CsA washout assays were performed with 
C2-9 cells. The night before the assay, cells were seeded out in a 96 well tissue culture plate with 
7,500 cells per well to yield 70-80% confluence on the day of the washout assay. There are 9 
timepoints (0, 15 min, 30 min, 45 min, 1 hr, 2 hr, 3 hr, 4 hr, and 5 hr) and each timepoint is 
performed in triplicate with CsA and with EtOH. Three wells served as a positive control that 
were continuously treated with CsA and 3 wells served as a negative control that were 
continuously treated with EtOH. In addition, 6 wells of uninfected cells were continuously 
incubated in cell culture media as a negative control for flow cytometry. Therefore, 66 wells 
were plated with 7,500 cells in each well.  
To begin the assay, a spinoculation mastermix of media was made for each experimental 
condition in a 15 ml conical tube with enough media to add 100 µl to each well. The cell culture 
media was incubated in a 37C water bath for 5-10 min to bring the temperature up from 4C but 
below or near 16C in order to synchronize infection. The mastermix contained C20 media, 5 
µg/µl polybrene, 2.5 µM CsA or EtOH, and 1/25 dilution of HIV-GFP virus. The media was 
aspirated from each well, except the negative control with uninfected cells, and 100 µl of 
spinoculation media was added. The 96 well plate was spinoculated at 1200 x g at 16C for 1 
hour and incubated at 16C for approximately 1 hour. The media from all of the wells, except the 
uninfected cells, was aspirated and the washout for the 0 hr timepoint was performed by adding 
200 µl warmed cell culture media. The other wells received 100 µl warmed CsA or EtOH media, 
and the plate was placed in the 37C incubator until the 15 min timepoint. The washout was 
performed at the 15-minute timepoint by aspirating the CsA and EtOH media from the 
appropriate wells and replacing it with 200 µl of warmed C20 media. The washouts for the 30 
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min, 45 min, 1 hr, 2 hr, 3 hr, 4 hr, and 5 hr timepoints were performed in the same manner, and 
then the plate was incubated at 37C for 2 days.  
Following the 2-day incubation, the cells were harvested. Media was aspirated from each 
well, 100 µl of PBS (Corning) was added to each well and aspirated, and then 100 µl of trypsin 
(Corning) was added to each well. The plate was incubated at 37C for 5 minutes until the cells 
detached and the cells were resuspended using a multichannel pipet. Then, 100 µl of 2% 
paraformaldehyde was added to each well, the plate edges were wrapped in parafilm and the 
entire plate was wrapped in foil and stored at 4C.  
To determine the percentage of cell successfully infected by HIV-GFP, flow cytometry 
was performed using a C6 Accuri flow cytometer to provide the percentage of GFP positive 
cells. Because the experiment was performed in triplicate, with 3 wells for each timepoint, the 
averages of the 3 wells for each timepoint and control were calculated. For each timepoint, the 
average percentage of GFP positive cells for the ethanol control was subtracted from the average 
percentage of GFP positive cells for CsA treatment to normalize the data. The standard deviation 
and standard error for the average of each timepoint were calculated. To calculate the half-life of 
uncoating, the two timepoints that half of the maximum percentage of GFP positive cells falls in 
were graphed, and the trendline equation was utilized. The highest percentage of GFP positive 
cells were normalized to 100% and the remaining of the data was calculated by dividing the 
percentage of GFP positive cells by the highest value of GFP positive cells and multiplied by 
100. The standard error was normalized in the same fashion, by dividing the original standard 
error by the highest percentage of GFP positive cells and multiplying by 100.  
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Viral Fusion Assay 
The viral fusion assay was conducted to study the rate at which the virus fused with the 
cell. The night before the assay, C20 and C20 2-9 cells were seeded out to obtain 7,500 cells/well 
in a 96 well plate and 70-80% confluence on the day of the assay. Three wells were needed for 
each timepoint (0 hr, 15 min, 30 min, 45 min, 1 hr, 2 hr, 3 hr, and 4 hr). For a positive control, 3 
wells for each cell line were continuously treated with the fusion inhibitor BafilomycinA (BafA) 
(company) and, as a negative control, 3 wells for each cell line were uninfected and continuously 
incubated in cell culture media. This resulted in 33 wells plated for each cell line.  
To begin the viral fusion assay, the media was aspirated from each well and a 
spinoculation mastermix media was made. This media contained C20 media, 2.5 µM CsA, 5 
µg/µl polybrene, and 1/25 dilution HIV-GFP, and 100 µl was added to each well except the 
BafA constant and uninfected wells. A separate spinoculation media mix was made that 
contained 10 nM BafA, in addition to the other components in the spinoculation mastermix, and 
100 µl was added to the BafA constant wells. The plate was spinoculated at 1200 x g at 16C for 
1 hour and incubated at 16C for 1 hour.  
Following spinoculation, the media was aspirated from all wells except the uninfected 
cells. The 0 hr timepoint was performed by adding 200 µl warmed BafA and CsA containing 
media to the appropriate wells and the BafA constant wells, and warmed C20 media with CsA 
was added to the remaining wells. The plate was placed in the 37C incubator until the 15min 
timepoint when the media was aspirated and 200 µl of BafA and CsA containing media was 
added to the appropriate wells. This BafA addition was continued in the same manner for the 30 
min, 45 min, 1 hr, 2 hr, 3 hr, and 4 hr timepoints. The 96 well plate was incubated at 37C for 1 
day. 
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Following incubation, the media was aspirated from all wells and 100 µl of warmed C20 
media was added to each well. The plate was then incubated at 37C for 1 day. To harvest the 
cells, the media was aspirated from each well and replaced with 100 µl of PBS, which was 
aspirated and replaced with 100 µl of trypsin. The plate was incubated at 37C until the cells 
detached from the plate. The cells were then resuspended by pipetting with a multichannel 
pipette. Next, 100 µl of 2% paraformaldehyde was added to each well to fix the cells. The plate’s 
edges were wrapped in parafilm, the entire plate was wrapped in foil, and the plate was stored at 
4C.   
Flow cytometry was run using a C6 Accuri flow cytometer to determine the percentage of 
cells infected by the virus and thus expressing GFP fluorescence. As this experiment was done in 
triplicate, the average of 3 wells for each timepoint and control was calculated. The standard 
deviation and standard error for each average timepoint was calculated. The values for each 
timepoint were normalized to the 0 hr timepoint being 0% GFP positive cells. To find the viral 
fusion half-life, the two timepoints that half of the maximum percentage of GFP positive cells 
falls in were graphed, and the trendline equation was utilized. The value of the highest 
percentage of GFP positive cells was normalized to 100% and the remaining values followed this 
trend by dividing by the highest value and multiplying by 100. The standard errors for each 
timepoint were converted to a new normalized value by dividing by the highest value for 
percentage of GFP positive cells and multiplying by 100.  
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Table 1. Hygromycin kill curve in C20 cells. Two hygromycin kill curves were established to 
determine the optimal amount of hygromycin to use when growing C20-TC cells under 
hygromycin selection. The concentration of hygromycin in each well of the 6-well plate for each 
experiment is shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Concentration of hygromycin 
Well Run 1 Run 2 
1 0 µg/ml 0 µg/ml 
2 100 µg/ml 50 µg/ml 
3 200 µg/ml 100 µg/ml 
4 300 µg/ml 150 µg/ml 
5 400 µg/ml 200 µg/ml 
6 500 µg/ml  
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Figure 4. Flow chart simplifying the steps of generating C20-TC cell line. Generation of the 
C20-TC cell line began with engineering TCSH virus and proceeded through the steps of the 
flowchart as shown.  
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Figure 5. Depiction of the process of growing up isolated clones. Once clones were isolated from 
10 cm plates, they were placed in a well of a 24-well plate and grown to confluency. As cells 
grew, they were transferred to each step of the flow chart.  
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Figure 6. A depiction of how to execute the dilution series to test for infectivity of HIV-GFP. 
This image was created by Dr. Amy Hulme. For infection, 2X polybrene media was added to 
wells H1 and H2, and 1X polybrene media was added to the remaining wells (G-A). For the 
serial dilution, 100 µl of HIV-GFP was added to H1/H2, mixed, and then 100 µl was added to 
G1/G2, and the dilution proceeded in the same manner.  
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RESULTS 
 
Generating C20-TC Cell Line 
Hygromycin kill curve.  A hygromycin kill curve was performed to establish the 
appropriate concentration of hygromycin to use when growing cells under selective pressure to 
establish a C20-TC cell line. The ideal concentration of drug would kill cells after 5 to 7 days. 
This timeframe allows ample time for the resistant cells to grow as well as for the drug to kill all 
of the cells that do not express the resistant gene. Any length of time longer than this would be 
inefficient when attempting to establish a cell line. Two separate experiments were done, each in 
a 6-well plate. The first experiment used 6 different concentrations of hygromycin, 0 µg/ml, 100 
µg/ml, 200 µg/ml, 300 µg/ml, and 400 µg/ml. All cells treated with 200 µg/ml or higher died 
within 5 days, and cells treated with 100 µg/ml died after 6 days. These results suggest that 200 
ug/ml may have been too high of a concentration of hygromycin because all of the cells died 
around the same time and earlier than desired. To better clarify which concentration would be 
best to grow cells under selective pressure, the hygromycin kill curve was repeated with lower 
concentrations. Cells treated with 150 µg/ml and 200 µg/ml died within 4 days, which was 
shorter than the desired time. Cells treated with 50 µg/ml were still alive after 6 days, which was 
longer than the desired length of time and it was unclear if the cells grown under these conditions 
would completely die off. The cells treated with 100 µg/ml died within 6 days which was within 
the target length of time, so this concentration of drug was chosen to use when the cell line was 
being generated. 
Once the concentration of hygromycin was determined, C20 cells were infected with 
TRIM-CypA expressing virus and grown in C20 media containing 100 µg/ml of hygromycin. 
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After at least 6 days had passed to allow selection of hygromycin resistant cells, the cells were 
then diluted to establish clones from a single cell. Single colonies were picked from dilutions of 
75 cells/plate and 100 cells/plate. In total 20 colonies were picked, grown, and passaged from a 
24 well plate to a 12 well plate. Of the 20 colonies picked, 14 colonies survived to establish a 
cell line. Each of the 14 colonies were used to make a whole cell lysate sample to test each of the 
cell lines for presence of TRIM-CypA using a western blot.  
Western blot to confirm presence of TRIM-CypA in cells. To confirm stable 
expression of TRIM-CypA in the newly established C20-TC cell lines, a western blot was done. 
A 3F10 anti-HA antibody was used to target the HA tag on TRIM-CypA. TCN14 cells were used 
as a positive control and had a band at 45 kDa, the correct size for TRIM-CypA (Figure 7). 
These cells were chosen as a positive control because they are CHME3 cells engineered to 
express TRIM-CypA using the same TCSH virus. As the parent cell line of TCN14, CHME3 
cells were used as a negative control and had no bands (Figure 7).  
Of the 14 cell lines isolated, 7 were tested for expression of TRIM-CypA and 5 were 
positive for TRIM-CypA expression (Figure 7). C1-5, C2-6, and C2-9 cells had the highest 
expression of TRIM-CypA, each with a dark band at 45 kD. C2-11 and C2-12 cells had 
moderately dark bands at 45 kD, but not as dark as C1-5, C2-6, and C2-9 cells. This could be due 
to the cells turning down expression of the TRIM-CypA gene. C1-7 and C1-8 cells had light 
bands near 45 kD that could be due to very low levels of expression of TRIM-CypA in the cell 
lines. Low levels of expression could also be due to human error while loading the wells of the 
gel causing some of the sample from the surrounding wells could have spilled over into the wells 
containing C1-7 and C1-8 samples, giving a false slightly positive result. Because they had the 
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best expression of TRIM-CypA, C1-5, C2-6, C2-9, C2-11, and C2-12 cell lines were chosen to 
continue further testing.    
            Infectivity of new cell lines. Infectivity assays were performed in 5 candidate cell lines 
to determine whether TRIM-CypA was functioning properly in the cell lines that had confirmed 
stable protein expression. When expressed by cells, TRIM-CypA binds to the viral capsid and 
blocks HIV-1 infection. CsA binds to TRIM-CypA, blocking its ability to inhibit infection. 
Therefore, each cell line was treated with either CsA or an EtOH control and infected with HIV-
GFP virus. HIV-GFP is a green fluorescent protein (GFP) reporter virus, meaning that when HIV 
inserts its DNA to establish infection of the target cell, it will also insert the GFP gene. Infected 
cells will then express GFP, and flow cytometry is used to determine the percentage of GFP 
positive or infected cells. TCN14 is a cell line that stably expresses TRIM-CypA and was used as 
a positive control. It is expected that the TCN14 cells will have a higher infectivity in the 
presence of CSA and a lower infectivity in the presence of EtOH. C20 is the parent cell line that 
does not express TRIM-CypA and was used as a negative control.  It is expected that the C20 
cells will have no change of infectivity when infected with HIV-GFP in the presence and 
absence of CSA. 
The name of each cell line tested and the infectivity of each at 1/64 dilution of virus is 
shown in Table 2. Infectivity at the lowest dilution of virus, 1/64, is focused on when analyzing 
these data because the infectivity is below 50%, which lowers the chance of 1 cell being infected 
by multiple viruses. For each cell line, the infectivity in the presence and absence of CsA was 
compared. TCN14 cells had infectivity of 15.07%-12.18% in the presence of CsA and 0.00%-
0.56% in the ethanol condition, indicating that the TRIM-CypA protein was properly functioning 
in this cell line (Table 2). At the 1/64 dilution of virus, C20 cells had infectivity of 45.45%-
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33.13% in the presence of CsA and 56.66%-50.97% in the ethanol condition, confirming that 
these cells did not express TRIM-CypA.  
Figure 8A shows the infectivity data from the C2-9 cell line tested in the two conditions. 
The C2-9 cells had significantly higher percentage of GFP positive cells when infection occurred 
in the presence of CSA than EtOH, as expected with a functioning TRIM-CypA protein. At 1/64 
dilution of virus, the C2-9 cell line infectivity was at 35.92% in comparison to 1.39% in the 
ethanol control. These data suggest that in the C2-9 cell line, TRIM-CypA is unable to restrict 
uncoating when the cells are treated with CsA but almost completely restricts infection in the 
ethanol control. Therefore, TRIM-CypA was properly functioning in the C2-9 cells. When 
compared to the TCN14 cells, TRIM-CypA in C2-9 cells was more effective. At the same 
dilution of virus TCN14 cells had 12.98% infectivity in CsA and 0.56% infectivity in ethanol. 
Although TCN14 cells had lower infectivity in ethanol at 1/64 dilution of virus, C2-9 cells had 
much higher infectivity in CsA. Figure 8B shows the infectivity data of C2-12 cells in the 
presence and absence of CsA for comparison with C2-9 cells. These cells did not show as much 
of a difference in infectivity in the two conditions as the C2-9 cells did. When treated with CsA, 
in 1/64 dilution of virus the C2-12 cells had 12.18% infected cells, which is much lower than the 
C2-9 cells had. In the ethanol control, C2-12 cells had 4.47% infectivity. This is much higher 
than the C2-9 cells and is undesirable because it indicated that TRIM-CypA is not restricting 
viral uncoating in as many cells as it does when expressed by the C2-9 cells. C2-9 was chosen as 
the cell line to use in further experiments because it had the highest infectivity in the presence of 
CsA and the lowest infectivity in ethanol when compared to all other cell lines, including the 
positive control.   
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Uncoating in C2-9 Cell Line 
Viral titration. To accurately study HIV-1 uncoating in C20 cells, the concentration of 
HIV-GFP to be used in the CsA washout and viral fusion assays was determined by a viral 
titration. An infectivity less than 50% was desired because it lowers the probability of having 
more than one virus infect each individual cell, which is important because the read out of the 
uncoating assay and viral fusion assay is an infected cell. One infected cell represents one 
uncoated virus in the CsA washout assay and one fused virus in the viral fusion assay.  
Two stocks of HIV-GFP, July 2017 and September 2017, were tested in a dilution series 
of infection in C20 cells. Figure 9 shows that the September 2017 stock of virus had higher 
percentages of infectivity at lower concentrations than the July 2017 stock, and was therefore 
chosen for future experiments. The September 2017 stock of virus was used for all experiments 
in this project at a 1/100 dilution. This concentration was decided based on the virus having 
45.09% infectivity at 1/64 dilution and 29.79% infectivity at 1/128 dilution (Figure 9). The cells 
that were not treated with virus that served as a negative control did not have exactly 0.00% GFP 
positive cells because there was some background fluorescence in the cells detected by the flow 
cytometer. Once the concentration of virus to be used was determined, the CsA washout assays 
and viral fusion assays were performed. 
CsA washout assay. To study the rate at which HIV-1 uncoats in microglial cells, the 
CsA washout assay was utilized in C2-9 cells. The cells were infected with HIV-GFP and treated 
with either CsA or the EtOH carrier control. CsA acted as a TRIM-CypA inhibitor to block the 
proteins ability to restrict HIV replication. The drugs were washed out at various timepoints and 
the percentage of GFP positive cells was determined by flow cytometry for each timepoint. 
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Expression of GFP by cells confirmed HIV-GFP infection and signified a successfully uncoated 
virus.  For more accurate results, each timepoint for both conditions was performed in triplicate. 
Figure 10 is representative data from one CsA washout assay. Figure 10A is the raw data 
graphed and Figure 10B is the data after results were normalized by subtracting the percent of 
GFP positive cells in the ethanol control. In Figure 10C, the highest percentage of GFP positive 
cells was normalized to 100% and the data was graphed. In the assays, GFP positive cells start to 
increase within the first hour of the experiment around 30-45 min.  In the experiment, the 
percentage of GFP positive cells levels off at 4 hours. At 2 hours postinfection in all 
experiments, over half of the total GFP positive cells had uncoated virus. In Figure 10, the half-
life of uncoating was calculated to be 50.2 min.  From 7 experiments the average half-life of 
uncoating in C2-9 cells was calculated to be 65.6 min (Table 3).  
Viral fusion assay. The uncoating half-lives calculated from the CsA washout assay 
include the timing of both viral fusion and uncoating. Viral fusion assays were conducted 
similarly to CsA washout assays, having the same timepoints but keeping CsA in the media and 
adding in a fusion inhibitor at each timepoint. At each washout timepoint, we can subtract out the 
timing of viral fusion using the results of a viral fusion assay that is done concurrently with the 
CsA washout assay. This gives a more accurate depiction of the timing of uncoating. The viral 
fusion assay in C2-9 cells was performed 4 times simultaneously with the CsA washout assay, 
using the fusion inhibitor BafA the first two experiments and NH4Cl the last two experiments, as 
well as once without a CsA washout assay. Each timepoint for each experiment was performed 
in triplicate, and the standard error for each is shown on the graphs. Representative data from one 
viral fusion assay is shown in Figure 11. Figure 11A is the raw data from the experiment and 
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Figure 11B is the data normalized to 0% fusion at the 0 hr timepoint. Figure 11C is the data with 
the highest percentage of GFP positive cells normalized to 100%.  
The average half-lives calculated from 4 viral fusion assays done concurrently with 
washouts was 40.9 min (Table 4). In comparison, the average uncoating half-life from these 
experiments was 63.3 min and the average difference between the uncoating half-life and viral 
fusion half-life was 22.3 min (Table 4). To compare the parent cell line with the newly 
established, TRIM-CypA expressing cell line, 2 fusion assays were performed simultaneously 
with C20 and C2-9 cells. From the 2 experiments shown in data Table 5, the average half-live of 
fusion in the C20 cells was 79.5 min and in the C2-9 cells was 63.3 min. The newly established 
cell line was found to fuse faster than the parent cell line.  
Effect of CsA in the C20 cell line. It was important to understand how CsA influenced 
overall infectivity in C2-9 cells because viral uncoating was studied in cells that were treated 
with this drug. C2-9 cells express TRIM-CypA and require CsA present for viral uncoating to 
occur in the cells, so it is impossible to study infectivity of the cells with CsA present and absent. 
Therefore, the C20 parent cell line of C2-9 was used in this investigation. To test infectivity, a 
serial dilution of virus was used to infect C20 cells in CsA and in an ethanol control. The 
experiment was repeated 3 times to ensure accuracy. As shown in Figure 12, it was observed that 
infectivity was slightly decreased in the presence of CsA when compared to ethanol. Average 
infectivity of the 3 experiments when 1/64 diluted virus was used to infect C20 cells treated with 
CsA was 4.54% while the same dilution of virus used to infect C20 cells treated with ethanol 
resulted in an average of 12.78% infectivity (Table 6). This could be due to CsA binding to host 
protein CypA and inhibiting the interaction between CypA and viral capsid. At dilutions of virus 
near ½, conclusions cannot be drawn because there is a higher probability that more than one 
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virus infects one cell. Because the read out of the assay is one infected cell, there is no way to tell 
whether the results at these lower dilutions accurately represent the amount of established 
infection.  
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Figure 7. Western blot to confirm presence of TRIM-CypA in new cell lines. 7 of the 14 cell 
lines were analyzed by Western Blot using a primary anti-HA antibody targeting the HA tag on 
TRIM-CypA. A standard protein ladder (Bio-Rad) was used. TCN14 cells, which are CHME3 
cells engineered to express TRIM-CypA, served as a positive control and CHME3 cells served as 
a negative control. The new cell lines under investigation were C1-5, C1-7, C1-8, C2-6, C2-9, 
C2-11, and C2-12.  
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Figure 8. Infectivity of the new cell lines compared to C20 and TCN14 cell lines in the presence 
and absence of CsA. Infectivity assays were performed in seven chosen new cell lines (C1-5, C2-
6, C2-6, C2-11, C2-12) to determine what effect CsA had on overall HIV-GFP infectivity of the 
cell line. The assays were conducted using the TCN14 cell line as a positive control and the C20 
cell line as a negative control.   A) Results of the infectivity assay with C2-9, C20, and TCN14 
cells. B) Results of the infectivity assay with C2-12, C20, and TCN14 cells.  
 
A 
B 
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Table 2. Infectivity of new cell lines with 1/64 dilution of virus in the presence and absence of 
CsA. To study how effective TRIM-CypA was in each newly established cell line, the cells were 
infected with HIV-GFP and treated with CsA, and the viral infectivity was compared to an 
ethanol control. A dilution of 1/64 was used for comparison because infectivity of the cells at 
this dilution was below 50%, lowering the probability of one cell being infected by more than 
one virus. The range of the results for each control, TCN14 and C20, is shown as these cell lines 
were tested multiple times, once with each new cell line, whereas the new cell lines were only 
tested once.   
 
 
 
 % GFP positive cells 
Cell line CsA EtOH 
C1-5 13.30 0.21 
C2-6 31.35 1.66 
C2-9 35.92 1.39 
C2-11 13.85 1.15 
C2-12 12.18 4.47 
TCN14 12.18-15.07 0.00-0.56 
C20 33.13-45.45 50.97-56.66 
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Figure 9. Dilution series of HIV-GFP virus stock. Two stocks of HIV-GFP virus, July 2017 and 
September 2017, were used to infect C20 cells at sequential dilutions to help determine the most 
suitable dilution of virus to use in future experiments.  
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Figure 10. A representative CsA washout assay. Data from the experiment on 12/14/2018 were 
chosen to represent all 7 of the CsA washout assays conducted because of the high percentage of 
living cells and an ideal ethanol control. A) Raw data results. B) Results after being normalized 
by subtracting the percentage of GFP positive cells in the ethanol control. C) Data graphed after 
the results were normalized by setting the highest percentage of GFP positive cells at 100%.  
 
A 
B 
C 
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Table 3.  CsA washout assays conducted with and without collecting viral fusion data. In each 
experiment, C2-9 cells were infected with HIV-GFP in the presence of CsA or an ethanol 
control, and the percentage of infected cells was determined by GFP fluorescence. Some CsA 
washout assays were performed side-by-side with viral fusion assays, while others were not. 
 
Date Uncoating half-life (min) Viral fusion data collected 
09/27/18 64.2 No 
10/04/18 85.1 No 
10/10/18 117.3 Yes 
11/03/18 58.3 Yes 
11/12/18 56.4 No 
12/05/18 27.4 Yes 
12/14/18 50.2 Yes 
Average 65.6  
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Figure 11. A representative viral fusion assay. Data from the experiment on 12/14/18 were 
chosen to represent all 5 viral fusion assays conducted because of the ideal number of living 
cells. A) Raw data. B) Data after the results were normalized to 0% GFP positive cells at the 0 hr 
timepoint. C) Results after the highest percentage of GFP positive cells was normalized to 100%. 
 
 
A 
B 
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Table 4. Side-by-side CsA washout and viral fusion assays. These assays were conducted with 
the same timepoints at the same time to study the rate of uncoating while accounting for the 
timing of viral fusion and holding conditions such as cellular and environmental factors constant. 
 
Date Fusion 
half-life (min) 
Uncoating 
half-life (min) 
Difference (min) 
10/10/18 89.6 117.3 27.7 
11/03/18 23.6 58.3 34.7 
12/05/18 21.9 27.4 5.5 
12/14/18 28.8 50.2 21.4 
Average 40.9 63.3 22.3 
Standard error 16.3 19.2  
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Table 5. Viral fusion assays that were conducted in C20 and C2-9 cells. These assays were 
conducted to compare the rate of viral fusion in C2-9 cells and the parent cell line, C20. 
 
Date Fusion C2-9 
half-life (min) 
Fusion C20 
half-life (min) 
09/10/18 36.9 67.9 
10/10/18 89.6 91.1 
Average 63.3 79.5 
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Figure 12. The effect of CsA on HIV-GFP infectivity in C20 cells. The data from the infectivity 
assay conducted on 02/09/18 was used to create a representative graph for all of the experiments. 
C20 cells were infected with different dilutions of HIV-GFP in the presence of CsA or an ethanol 
control. The percentage of infected cells was determined by percentage of GFP positive cells. 
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Table 6. The effect of CsA on 1/64 dilution of HIV-GFP in C20 cells. The infectivity of different 
dilutions of HIV-GFP was tested in the presence and absence of CsA to determine the effect of 
CsA on infectivity. The dilution of 1/64 was used during analytics to ensure accuracy.  
 
Date Avg. % GFP positive 
cells in CsA 
Avg. % GFP positive 
cells in EtOH 
02/05/18 4.08 11.11 
02/09/18 4.53 13.83 
03/08/18 5.02 11.72 
Average 4.54 12.78 
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DISCUSSION 
 
            CsA washout assays have been used to study uncoating kinetics in various cell lines 
including Owl Monkey Kidney (OMK) cells, a TRIM-CypA expressing HeLa cell line (HeLa-
TC), and now a TRIM-CypA expressing microglial cell line (C2-9). C2-9 cells had an average 
uncoating half-life of 63.3 min, while other studies found the uncoating half-life was near 64 min 
in OMK cells and 37 min in HeLa-TC cells (Table 4; Hulme et al., 2015). The timing of viral 
fusion is essential to consider when comparing uncoating half-lives to ensure that a discrepancy 
in uncoating kinetics is not due to delayed or accelerated viral fusion. The average fusion half-
life in C2-9 cells was 40.9 min, in OMK cells was near 19 min, and in HeLa-TC cells was near 
28 min (Table 4; Hulme et al., 2015). Virus in OMK cells fused faster than the C2-9 and HeLa-
TC cells, yet virus in OMK cells uncoated slower than in the C2-9 and HeLa-TC cells. This 
information confirms that the delay of uncoating observed in OMK cells was not due to a delay 
in viral fusion.  When subtracting the average half-life of viral fusion from the average uncoating 
half-life, the difference was 22 min in C2-9 cells, 45 min in OMK cells, and 9 min in HeLa-TC 
cells (Table 4; Hulme et al., 2015). It is not surprising that the timing of uncoating in C2-9 cells 
is more similar to HeLa-TC cells than OMK cells because HeLa cells are a human cell line while 
OMK cells are not.  
            An in situ uncoating assay in C2-9 cells would be an alternative way to confirm the rate 
of uncoating and viral fusion of HIV-1 in microglial cells (Yamashita et al., 2007). This assay 
uses a dual fluorescently labeled virus containing GFP-Vpr to visualize all virions and S15-
mCherry to visualize virions that have not yet fused, as well as CA staining to determine if 
uncoating has occurred. At different timepoints post-infection, cells are stained for CA protein 
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using an anti-CA primary antibody and a fluorescently labeled secondary antibody (Yamashita et 
al., 2007). The cells are imaged to determine the amount of GFP positive virions for each 
timepoint. These virions are then examined for S15-mCherry signal, expressed by unfused virus, 
and CA protein signal, expressed by viral complexes that have not yet uncoated (Yamashita et 
al., 2007). Data collected from this assay can determine the amount of fusion and uncoating that 
occurs over time. In C2-9 cells, it is expected that the number of fused GFP-Vpr positive 
particles would significantly increase between 30 min and 1 hr, and the number of particles 
positive for CA staining would significantly decrease at approximately 1 hr as uncoating occurs.             
            The in situ uncoating assay is performed in vivo, like the CsA washout assay, and would 
therefore produce data that is easily comparable to the data obtained in this study. The benefit of 
conducting both the CsA washout assay and the in situ uncoating assay in C2-9 cells is obtaining 
data regarding uncoating using different methods with different benefits. The CsA washout assay 
read out is one infected cell, which removes any replication incompetent virus that the in situ 
assay includes. The CsA washout assay is conducted in living cells over time, allowing viral 
replication to run its course, which may provide more beneficial data than the in situ assay that 
fixes cells at various timepoints. A benefit for the in situ uncoating assay is the ability to directly 
visualize CA protein to see coated and uncoated virions in each individual cell. This assay 
directly detects CA protein while the CsA washout assay uses the ability of TRIM-CypA to 
restrict infection as an indirect method to detect CA. 
            The variation in the CsA washout results seen in this study is most likely due to a change 
in cellular environment (Table 4). Minor changes in the execution of each experiment such as 
how long the cells incubated at 16C following spinoculation could slightly influence results. 
Specific bottles of media used, the amount of time cells were in culture, and the exact 
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temperature of reagents could also cause a variation in kinetics of steps of viral infectivity in 
cells. There was an attempt to control all confounding variables by conducting all runs of the 
same experiments within a reasonable amount of time, around 2 months, and making note to use 
the same bottle of media if possible. Reagents were used and stored in the same manner each 
experiment in an attempt to decrease any chance that reagents may have an unintentional effect 
on experimental results. The timing of the steps of HIV-GFP infectivity in cells is dependent on 
viral and cellular factors, which could change with the environment. To account for variation, 
each timepoint is done in triplicate and the assay was run 7 times.   
            Cellular factors may also contribute to the differences observed in viral fusion and 
uncoating kinetics in OMK, C2-9, and HeLa-TC cells. Cellular factors may be expressed in one 
cell line at a different rate than the others. For example, the microtubule motor protein KIF5B 
has been shown to mediate uncoating in cooperation with NUP358 in HeLa cells and monocyte 
derived macrophages (Dharan et al., 2016). To determine if the level of expression of KIF5B has 
an effect on the kinetics of uncoating, this cellular factor could be investigated in OMK, C2-9, 
and HeLa cells. To examine the expression of KIF5B in each cell line, quantitative PCR (qPCR) 
could be utilized to quantify expression. I would expect to see a significant difference in 
expression of this protein when comparing the human cell lines, C2-9 and HeLa-TC, to the OMK 
cells because they originate from different species and have differing uncoating kinetics. A 
proximal ligation assay could be utilized with antibodies specific to KIF5B and CA protein to 
determine if this cellular factor interacts directly or indirectly with the capsid in each cell line 
(Dharan et al., 2016). From this assay, I would expect to see KIF5B interacting directly with the 
viral capsid in human cell lines, which would produce many fluorescent puncta as the antibodies 
associated with KIF5B and CA interact. This finding could attribute the faster uncoating kinetics 
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observed in these cells to KIF5B. In OMK cells, an indirect interaction between KIF5B and CA 
protein would be expected and marked by a lack of fluorescent puncta leading to delayed 
uncoating observed in these cells.  If the expression of KIF5B and the interaction of KIF5B with 
CA protein differs as I am suggesting, then this molecule could be a cellular factor that 
contributes to the difference of uncoating kinetics seen in the human cell lines and OMK cells.  
            To determine which model of uncoating is most likely, it is important to compare the 
timing of viral fusion and uncoating to estimate how quickly after fusion a virus uncoats. In the 
side-by-side assays, the average half-life of viral fusion was 40.9 min and the average half-life of 
uncoating was 63.3 min (Table 4). These data discredit the likelihood of the rapid uncoating 
model because if virus rapidly uncoated immediately following viral fusion, the half-life of 
uncoating would be only minutes longer than the half-life of viral fusion. The rapid uncoating 
model has been widely discredited in the field because of overwhelming evidence of CA present 
in the cytoplasm associated with RTC and cellular host factors (McDonald et al., 2002; Peng et 
al., 2014). Because there is a calculated uncoating half-life of 22.3 min when the half-life of viral 
fusion is accounted for, the cytoplasmic uncoating model or nuclear pore complex model of 
uncoating is more likely with these data (Table 4). Experimentation in HeLa cells discovered an 
approximate nuclear import time of 4.3 hours postinfection (± 2.6) using live cell imaging to 
visualize the nuclear import of fluorescently labeled virions by staining the nuclear membrane 
(Burdick et al., 2017). When the average uncoating half-life of HeLa cells of 37 min is taken into 
consideration with this nuclear import time, the cytoplasmic uncoating model seems to be more 
likely than the nuclear pore complex model.  
            In C2-9 cells, assays measuring nuclear import kinetics would help determine when 
uncoating occurs in relation to nuclear import to help differentiate between uncoating models. To 
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do this, an in situ uncoating experiment could be performed that includes staining the nucleus 
like that was done in the HeLa cells (Burdick et al., 2017).  This assay would be advantageous 
because of the ability to visualize both coated and uncoated viral complexes in relation to the 
nucleus. Using images from this assay, it may be possible to distinguish between the cytoplasmic 
uncoating model and nuclear pore complex uncoating model by staining the nucleus and 
considering the distance between coated virions and the nucleus before the intact capsid 
undergoes uncoating. Another way to determine nuclear import kinetics is by measuring the 
amount of 2-LTR circular viral DNA. These DNA complexes form only after synthesis of linear 
viral DNA and nuclear import, likely because the nucleus provides the necessary environment 
for circularization of retroviral DNA (Withers-Ward, Kitamura, Barnes, & Coffin, 1994).  The 
method of qPCR can be used to quantify 2-LTR products at different timepoints post-infection 
using primers specific to this product (Butler, Hansen, & Bushman, 2001). The number of 2-LTR 
products at each timepoint would signify the amount of nuclear import that has occurred by that 
time post-infection.  This method could be utilized to investigate the kinetics of nuclear import in 
C2-9 cells as it is specific and rapid, but it does not offer the ability to visualize a virion entering 
the nucleus like fluorescence microscopy does. If uncoating occurs in C2-9 cells following the 
cytoplasmic uncoating model, images from the in situ staining assay would show a considerable 
amount of distance between coated virions and the nucleus, and qPCR would produce results in 
which there would be a large increase of 2-LTR copies observed at a post-infection timepoint 
much later than 1 hr, as the established half-life of uncoating in C2-9 cells is 63.3 min (Table 4). 
If the nuclear pore complex model is more characteristic of uncoating in these cells, then images 
from the in situ staining experiment would show negligible distance between the coated virions 
and nucleus, and qPCR would show a large increase in 2-LTR copies near the 1 hr post-infection 
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timepoint. The results from images obtained from the in situ assays combined with the kinetics 
of uncoating and nuclear import could potentially be enough evidence to conclude which model 
of uncoating occurs in C2-9 cells.  
            Repeating assays that measure fusion, uncoating, and nuclear import in different cell 
types could help decipher if uncoating follows different models in different cell types. The focus 
of these experiments should be cells that express a CD4 receptor on their surface and are 
therefore natural targets of HIV-1. Uncoating kinetics have been characterized in the microglial 
cell line CHME3 using the TRIM-CypA expressing daughter cell line TCN14 and now in a 
microglial cell line that is more characteristic of primary microglial cells, C20, using the TRIM-
CypA expressing daughter cell line C2-9 (Hulme, 2019). The next cell type to be tested could be 
dendritic cells, as they function as a messenger in the immune system and express CD4, making 
them a natural HIV-1 target. To test dendritic cells, the human monocytic cell line THP-1 can be 
differentiated into mature dendritic cells when cultured into serum free-media containing GM-
CSF, TNF-alpha, and ionomycin (Berges et al., 2005). This cell line derived from human 
monocytes is ideal to use in this investigation simply because it originates from humans, which 
are the focus of this HIV-1 study.  
            Virus with mutated capsid is used to study the role that CA protein has in HIV-1 
uncoating and infectivity. The rate of uncoating is important to study because it effects overall 
viral infectivity. A92E is a CypA restricted mutant that significantly increases the rate of 
uncoating and has a decrease of infectivity (Hulme et al., 2015; Qi, Yang, & Aiken, 2008). E45A 
is a mutant that increases capsid core stability, delays uncoating and also has a decrease of 
infectivity (Hulme et al., 2015; von Schwelder et al., 2003). Mutant N74D was found to delay 
uncoating, even more so in HeLa-TC cells than in OMK cells, and has a decrease of infectivity 
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(Ambrose et al., 2012; Hulme et al., 2015). The difference in severity of delay of uncoating with 
mutant N74D further supports the hypothesis that the difference of cellular environment in the 
HeLa-TC cells and OMK cells has an effect on HIV-1 uncoating. It would be beneficial to 
conduct CsA washout assays in C2-9 cells with capsid mutants in the future to investigate how 
the environment of this cell line interacts with CA protein and what effect that has on uncoating. 
Data collected could be compared to the previously reported data on capsid mutants in OMK and 
HeLa-TC cells, and any differences in the kinetics of uncoating of capsid mutant virus may 
implicate cellular factors that are different among these cell lines. New cellular factors could be 
potentially identified by discerning any differences in the kinetics of uncoating of mutant virus 
between the cell lines and comparing global gene expression of the cell lines.  
            From the use of capsid mutant virus, it appears that if uncoating occurs at a faster or 
slower rate than the wild type rate then infectivity is decreased. This makes the step of uncoating 
a point of interest when considering potential drug targets with the aim of decreasing viral 
infectivity. There are currently no antiretroviral pharmaceuticals designed to target the step of 
uncoating. BI-2 and PF74 are drugs that use similar mechanisms to bind to the capsid to block 
HIV-1 infection and are often used in research but were discontinued during pharmaceutical 
development (Fricke, Buffone, Opp, Valle-Casuso, & Diaz-Griffero, 2014; Shi, Zhou, Shah, 
Aiken, & Whitby, 2010). As more research is done on uncoating, it is hoped that this step of viral 
replication can serve as a new drug target that is used to improve the lives of those affected by 
HIV-1. 
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